» Articles » PMID: 38673487

Optic Nerve Neuroprotection in Glaucoma: A Narrative Review

Overview
Journal J Clin Med
Specialty General Medicine
Date 2024 Apr 27
PMID 38673487
Authors
Affiliations
Soon will be listed here.
Abstract

In recent years, researchers have been interested in neuroprotective therapies as a cutting-edge therapeutic strategy to treat neurodegenerative disorders by shielding the brain system from harmful events. Millions of individuals worldwide suffer from glaucoma, an ocular neurodegenerative disease characterized by gradual excavation of the optic nerve head, retinal axonal damage, and consequent visual loss. The pathology's molecular cause is still mostly unknown, and the current treatments are not able to alter the disease's natural progression. Thus, the modern approach to treating glaucoma consists of prescribing medications with neuroprotective properties, in line with the treatment strategy suggested for other neurodegenerative diseases. For this reason, several naturally derived compounds, including nicotinamide and citicoline, have been studied throughout time to try to improve glaucoma management by exploiting their neuroprotective properties. The purpose of this review is to examine the naturally derived compounds that are currently utilized in clinical practice for neuroprotection in glaucomatous patients based on scientific data, emphasizing these compounds' pivotal mechanism of action as well as their proven therapeutic and neuroprotective benefits.

Citing Articles

The Role of Diet and Oral Supplementation for the Management of Diabetic Retinopathy and Diabetic Macular Edema: A Narrative Review.

DAngelo A, Lixi F, Vitiello L, Gagliardi V, Pellegrino A, Giannaccare G Biomed Res Int. 2025; 2025:6654976.

PMID: 40041571 PMC: 11876532. DOI: 10.1155/bmri/6654976.


Exosomes in Regulating miRNAs for Biomarkers of Neurodegenerative Disorders.

Sivalingam A, Sureshkumar D Mol Neurobiol. 2025; .

PMID: 39918711 DOI: 10.1007/s12035-025-04733-8.


Effect of the Mediterranean Diet (MeDi) on the Progression of Retinal Disease: A Narrative Review.

Sbai O, Torrisi F, Fabrizio F, Rabbeni G, Perrone L Nutrients. 2024; 16(18).

PMID: 39339769 PMC: 11434766. DOI: 10.3390/nu16183169.


Glaucoma: Current and New Therapeutic Approaches.

Lee H, Tsung T, Tsai Y, Chen Y, Lu D Biomedicines. 2024; 12(9).

PMID: 39335514 PMC: 11429057. DOI: 10.3390/biomedicines12092000.


NAD+ and Niacin Supplementation as Possible Treatments for Glaucoma and Age-Related Macular Degeneration: A Narrative Review.

Gemae M, Bassi M, Wang P, Chin E, Almeida D Nutrients. 2024; 16(16).

PMID: 39203931 PMC: 11357639. DOI: 10.3390/nu16162795.


References
1.
Garcia-Medina J, Garcia-Medina M, Garrido-Fernandez P, Galvan-Espinosa J, Garcia-Maturana C, Zanon-Moreno V . A two-year follow-up of oral antioxidant supplementation in primary open-angle glaucoma: an open-label, randomized, controlled trial. Acta Ophthalmol. 2014; 93(6):546-54. DOI: 10.1111/aos.12629. View

2.
Messina S, Dawson Jr R . Attenuation of oxidative damage to DNA by taurine and taurine analogs. Adv Exp Med Biol. 2002; 483:355-67. DOI: 10.1007/0-306-46838-7_40. View

3.
Mustacich D, Bruno R, Traber M . Vitamin E. Vitam Horm. 2007; 76:1-21. DOI: 10.1016/S0083-6729(07)76001-6. View

4.
Caprioli J, Sears M . Forskolin lowers intraocular pressure in rabbits, monkeys, and man. Lancet. 1983; 1(8331):958-60. DOI: 10.1016/s0140-6736(83)92084-6. View

5.
Eberhardt R, Birbamer G, Gerstenbrand F, Rainer E, Traegner H . Citicoline in the treatment of Parkinson's disease. Clin Ther. 1990; 12(6):489-95. View